Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis
JEADV Clinical Practice · 27.07.2026
DOI: 10.1002/jvc2.70326 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 27.07.2026. Verfasst von So Yun Park und 6 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases. The patient remained in sustained remission for 3 years without adverse events, supporting the potential efficacy and safety of concurrent biologic therapy targeting distinct Th17 and Th2 pathways in overlapping immune‐mediated skin disorders.
Zitieren
APA
Park, S. Y., Park, M., Gwang, H. E., Hong, N., Jung, H. J., Park, M. Y., & Ahn, J. (2026). Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70326
Vancouver
Park SY, Park M, Gwang HE, Hong N, Jung HJ, Park MY, et al. Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70326
BibTeX
@article{Park2026,
author = {Park, So Yun and Park, Minjung and Gwang, Ho Eun and Hong, Narang and Jung, Hye Jung and Park, Mi Youn and Ahn, Jiyoung},
title = {Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis},
journal = {JEADV Clinical Practice},
year = {2026},
doi = {10.1002/jvc2.70326}
}
EUVIMED